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Editors: Anton N. Sidawy and Bruce A. PerlerEndovascular stent graft repair of acute catastrophes of the descending
thoracic aorta: Multicenter clinical trial
Richard P. Cambria, Robert S. Crawford, Jae-Sung Cho, Joseph Bavaria, Mark
Farber, W. Anthony Lee, Venkatesh Ramaiah, Christopher J. Kwolek, for the
GORE TAG Investigators
Objective: Thoracic endovascular aortic repair (TEVAR) is applicable to
a spectrum of thoracic aortic pathology with half of the procedures per-
formed world-wide for indications other than degenerative aneurysm of
the descending thoracic aorta (DTA). This multicenter, prospective study
queried perioperative and one-year results of TEVAR using the commercially
available GORE TAG device, in the treatment of acute complicated Type B
dissection (cTBD), traumatic aortic tear (TT), and ruptured degenerative
aneurysm (RDA) of the DTA.
Methods: This prospective, non-randomized, literature controlled study
included 59 patients; cTBD, nZ 19; RDA, nZ 20; TT, nZ 20. The primary
end-point was the composite of death and total paraplegia in subjects at
 30 days post-treatment compared with a cohort from current literature.
Secondary end-points included adverse events related to device, procedural
and systemic complications, and one-year survival.
Results: All 59 patients had successful endoprosthesis deployment. Fifteen
of 19 (79%) patients in the cTBD group had either rupture or malperfusion
syndromes at presentation. Combined 30-day mortality/paraplegia rate
was 13.6% (8/59), with seven (11.9%) deaths (cTBD [3], RDA [3] and TT [1])
and 1 (TT, 1.7%) case of paraplegia. The primary end-point for the TEVAR
cohort was significantly lower (PZ .008) when compared with a composite
literature control of 800 patients (combined 30-day mortality/paraplegia
of 29.6%). Thirty-day complications of any nature occurred in 48 (81%)
patients; 11 (18.6%) were device related, and 43 (73%) experienced one or
more systemic adverse events. Six (10%) patients required additional TEVAR
implantations and 3 (5%) patients (one in each pathology group) required
conversion to open surgery. Seventeen (29%) patients had endoleaks of
any kind or degree through 30 days; cTBD (7), TT (2), RDA (8). Nine patients
(15.3%) had perioperative strokes with two resultant deaths. During mean
follow-up time of 409  309 days, an additional 12 patients died, one
patient required open conversion (cTBD), and two patients had major device
related events. Actuarial survival at one year was 66% (range, 52%-77%) for
the entire cohort; (cTBD) 79% (range, 53%-92%), (TT) 79% (range, 53%-92%)
and (RDA) 37% (range, 16%-59%). On regression analysis, age at treatment
(1.05 [range, 1.01-1.09]; PZ .008) and chronic obstructive pulmonary
disease (COPD) (4.3 [range, 1.3-14.4]; PZ .02) were predictive of death
at one year.
Conclusion: This study confirmed treatment advantages for TEVAR for
thoracic aortic catastrophes when compared with literature-based results
of open repair. One-year treatment results indicate a low incidence of
graft-related complications. TEVAR is the preferred initial treatment for
the DTA catastrophes studied herein.* Full articles available online at www.jvascsurg.org
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doi:10.1016/S1078-5884(09)00532-2Defining high-risk patients for endovascular aneurysm repair: A national
analysis
Natalia Egorova, Jeannine K. Giacovelli, Annetine Gelijns, Giampaolo Greco,
Alan Moskowitz, James McKinsey, K. Craig Kent
Background: Endovascular aneurysm repair (EVAR) is commonly used as
a minimally invasive technique for repairing infrarenal aortic aneurysms.
There have been recent concerns that a subset of high-risk patients experi-
ence unfavorable outcomes with this intervention. To determine whether
such a high-risk cohort exists and to identify the characteristics of these
patients, we analyzed the outcomes of Medicare patients treated with EVAR
from 2000-2006.
Methods: We identified 66,943 patients who underwent EVAR from Inpatient
Medicare database. The overall 30-day mortality was 1.6%. A risk model for
perioperativemortality was developed by randomly selecting 44,630 patients;
the other one third of the dataset was used to validate the model. The model
was deemed reliable (Hosmer-Lemeshow statistics were PZ .25 for the
development, PZ .24 for the validation model) and accurate (cZ 0.735
and cZ 0.731 for the development and the validation model, respectively).
Results: In our scoring system, where scores ranged between 1 and 7, the
following were identified as significant baseline factors that predict
mortality: renal failure with dialysis (scoreZ 7); renal failure without dial-
ysis (scoreZ 3); clinically significant lower extremity ischemia (scoreZ 5);
patient age 85 years (scoreZ 3), 75-84 years (scoreZ 2), 70-74 years
(scoreZ 1); heart failure (scoreZ 3); chronic liver disease (scoreZ 3);
female gender (scoreZ 2); neurological disorders (scoreZ 2); chronic
pulmonary disease (scoreZ 2); surgeon experience in EVAR <3 procedures
(scoreZ 1); and hospital annual volume in EVAR <7 procedures (scoreZ 1).
The majority of Medicare patients who were treated (96.6%, nZ 64,651)
had a score of 9 or less, which correlated with a mortality <5%. Only 3.4%
of patients had a mortality 5% and 0.8% of patients (nZ 509) had a score
of 13 or higher, which correlated with a mortality >10%.
Conclusion: We conclude that there is a high-risk cohort of patients that
should not be treated with EVAR because of prohibitively high mortality;
however, this cohort is small. Our scoring system, which is based on patient
and institutional factors, provides criteria that can be easily used by clini-
cians to quantify perioperative risk for EVAR candidates.Safety and efficacy of carotid angioplasty and stenting for radiation-
associated carotid artery stenosis: Analysis of restenosis and embolic
potential
Mikel Sadek, Neal S. Cayne, Hyun J. Shin, Irene C. Turnbull, Michael L. Marin,
Peter L. Faries
Introduction: Prior neck irradiation may induce atherosclerosis in the
carotid artery and is considered an indication for carotid angioplasty and
stenting (CAS). This study sought to evaluate the effect of neck radiation
therapy (XRT) on the rate of restenosis and embolic potential in patients
undergoing CAS.
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(XRT [NZ 28], non-XRT [NZ 182]). Mean follow-up was 347  339 days
(median, 305 days; range, 16-1354 days). Duplex velocity criteria for reste-
nosis after CAS were: >50% restenosis (peak systolic velocity [PSV] > 125
cm/sec, end diastolic velocity [EDV] 40-99 cm/sec, and internal carotid
artery to common carotid artery systolic ratio [ICA/CCA] > 2.0); >70% rest-
enosis (PSV>230 cm/sec, EDV>100 cm/sec, and ICA/CCA ratio >4.0). Rest-
enosis >70% was confirmed by digital subtraction angiography. Additional
endpoints included groin hematoma, groin pseudoaneurysm, myocardial
infarction, stroke, mortality, and the combined myocardial infarction/
stroke/mortality rate. Captured particulate data was obtained from micro-
porous filters used during CAS. Nineteen XRT and 128 non-XRT consecutive
filters were analyzed. Photomicroscopy was performed along three axes
for each filter, and the quantity and size of the captured particles were
analyzed using video image analysis software.
Results: There were more men (XRT: 85.7% vs. non-XRT: 52.8%, P < .001)
and prior surgical neck dissections in the XRT patients (XRT: 82.1% vs. non-
XRT: 4.7%, P < .001). Pre-procedural stenosis did not differ significantly be-
tweeen the two groups (XRT: 86.5%  8.9% [range, 70%-99%] vs. non-XRT:
85.5%  8.7% [range 70%-99%], PZ NS). Perioperative outcomes, including
the composite 30 day stroke/myocardial infarction/mortality rate did not
differ significantly between the two groups (XRT: 0% vs. non-XRT: 3.2%,
PZ NS). Twelve-month freedom from restenosis rates did not differ signifi-
cantly at the 50% threshold (XRT: 95.5% vs. non-XRT: 90.3%, PZ NS) or at the
70% threshold (XRT: 95.5% vs. non-XRT: 96.5%, PZ NS). Target lesion revas-
cularization did not differ significantly (XRT: 0% vs. non-XRT: 0.5%, PZ NS).
Photomicroscopy demonstrated a trend towards increased particle number
and size in the XRT filters, however the results did not achieve statistical
significance: particle number (XRT: 9.8  8.4 vs. non-XRT: 9.6  11.7,
PZ NS), %patients with particle size >1000 mm (XRT: 47.4% vs. non-XRT:
30.5%, PZ NS).
Conclusions: This study suggests that the durability of CAS and the charac-
teristics of captured embolic particles are not altered by a history of neck
XRT. This supports the safety and efficacy of CAS for the treatment of
patients with a history of neck XRT. Prior neck XRT may predispose the
patient to the de novo development of stenoses at locations that were not
previously treated.Endovascular treatment of spontaneous dissections of the superior
mesenteric artery
Ryan M. Gobble, Eliott R. Brill, Caron B. Rockman, Elizabeth M. Hecht,
Patrick J. Lamparello, Glenn R. Jacobowitz, Thomas S. Maldonado
Background: Spontaneous dissection of the superior mesenteric artery
(SMA) is exceedingly rare. Treatment options range from observation to an-
ticoagulation to open surgery or endovascular repair. We present our expe-
rience to date in the management of isolated SMA dissections.
Methods: A retrospective review of the vascular surgery and radiology
databases from 1998 to 2008 was performed. In general, incidental radio-
logic findings of a dissection were managed expectantly. The decision to
intervene was based on anatomic suitability, patient comorbidities and
symptoms, and physician preference. Endovascular stents were placed using
a brachial approach, with the choice of stent determined by physician
preference. Patients who underwent endovascular stent placement (ESP)
were maintained on antiplatelet therapy for 6 months postoperatively.
Follow-up consisted of yearly office visits and adjunctive computerized
tomography (CT) or magnetic resonance imaging (MRI) when clinically
indicated.
Results: CT or MRI imaging identified nine patients (7 men, 2 women) with
an isolated SMA dissection. One patient also had a concomitant celiac artery
dissection. Median age was 70 years (range, 46-73 years). Median follow-up
time was 32 months (range, 13.8-62.5 months). Presentations included an
incidental radiologic finding in three patients and acute onset abdominal
pain in six. Treatment included expectant management in four patients, an-
ticoagulation in two, and ESP in three. ESP was performed primarily in two
patients and in a third patient after initial management with anticoagulation
failed. The reduction in the diameter of the true lumen was significantly
greater in patients treated with ESP vs patients who were successfully
managed expectantly or with anticoagulation (FZ 15.59, P < .005). No
procedural complications were associated with ESP.
Conclusions: An isolated SMA dissection is a rare entity that may be managed
successfully in a variety of ways based on clinical presentation. Endovascularstenting can be performed with good results and may be the preferred
treatment in patients with symptomatic isolated SMA dissections.Prediction rule for cardiovascular events and mortality in peripheral
arterial disease patients: Data from the prospective Second
Manifestations of ARTerial disease (SMART) cohort study
Ralf W. Sprengers, Kristel J.M. Janssen, Frans L. Moll, Marianne C. Verhaar,
Yolanda van der Graaf, on behalf of the SMART Study Group
Background: Patients with peripheral arterial disease (PAD) are at high risk
of secondary cardiovascular death and events such as myocardial infarction
or stroke. To minimize this elevated risk, cardiovascular risk factors should
be treated in all PAD patients. Secondary risk management may benefit from
a prediction tool to identify PAD patients at the highest risk who could be
referred for an additional extensive workup. Stratifying PAD patients accord-
ing to their risk of secondary events could aid in achieving optimal therapy
compliance. To this end we developed a prediction model for secondary
cardiovascular events in PAD patients.
Methods: The model was developed using data from 800 PAD patients who
participated in the Second Manifestations of ARTerial disease (SMART) cohort
study. From the baseline characteristics, 13 candidate predictors were
selected for the model development. Missing values were imputed by means
of single regression imputation. Continuous predictors were truncated and
transformed where necessary, followed by model reduction by means of
backward stepwise selection. To correct for over-fitting, a bootstrapping
technique was applied. Finally, a score chart was created that divides
patients in four risk categories that have been linked to the risk of a cardio-
vascular event during 1- and 5-year follow-up.
Results: During a mean follow-up of 4.7 years, 120 events occurred (27%
nonfatal myocardial infarction, 21% nonfatal stroke, and 52% mortality from
vascular causes), corresponding to a 1- and 5-year cumulative incidence of
3.1% and 13.2%, respectively. Important predictors for the secondary risk
of a cardiovascular event are age, history of symptomatic cardiovascular
disease, systolic blood pressure, high-density lipoprotein cholesterol,
smoking behavior, ankle-brachial pressure index, and creatinine level. The
risk of a cardiovascular event in a patient as predicted by the model was
0% to 10% and 1% to 28% for the four risk categories at 1- and 5-year
follow-up, respectively. The discriminating capacity of the prediction
model, indicated by the c statistic, was 0.76 (95% confidence interval,
0.71-0.80).
Conclusion: A prediction model can be used to predict secondary cardiovas-
cular risk in PAD patients. We propose such a prediction model to allow for
the identification of PAD patients at the highest risk of a cardiovascular
event or cardiovascular death, which may be a viable tool in vascular
secondary health care practice.DNA-Array of gene variants in venous leg ulcers: Detection of prognostic
indicators
Donato Gemmati, Federica Federici, Linda Catozzi, Sergio Gianesini,
Giovanna Tacconi, Gian L. Scapoli, Paolo Zamboni
Objective: Wound healing in venous leg ulcer (VLU) is a multi-step process
involving complex pathways. Scanty knowledge at molecular level hinders
clinical assessment and treatment. Anomalous handling of local iron over-
load, as well as unbalancing in matrix metalloproteinases (MMPs) and trans-
glutaminase, has a recognized role in VLU establishment. We selected
a number of single nucleotide polymorphisms (SNPs) in candidate genes
(HFE, FPN1, MMP12, and FXIII) involved in VLU to identify potentially prog-
nostic markers by means of DNA-array technology.
Methods and Results: The DNA-array-genotyping was assessed in 638
subjects for the following SNPs: HFE (C282g, H63D), FPN1 (e8CG), MMP12
(e82AG) and FXIII (V34L). Of the subjects, 221 were affected by VLU (171
primary and 50 post-thrombosis), 112 by severe chronic venous disease
(CVD) (CEAP, C3-C4), while 305 were matched healthy controls. The HFE
and FXIII SNPs had been previously genotyped by conventional polymerase
change reaction (PCR)-methods on the same group of subjects (J Vasc Surg
2005;42:309; J Vasc Surg 2006;44:554; J Vasc Surg 2006;44:815). For the
purpose of DNA-array, they were re-genotyped by means of array-techniques
resulting in a 100% matching. Intergroup statistical comparisons were
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CVD risk of 4.3 (95% CI, 1.6-12) and a VLU risk of 5.2 (95% CI, 1.9-15) virtually
the same among primary VLU (4.98; 95% CI, 1.82-14.9). The MMP12 e82AA
genotype had a VLU risk of 1.96 (95% CI, 1.18-3.2) only in primary VLU
(PZ .01). In the genotype-ulcer size association studies, from a subgroup
of 167 cases, we observed a smaller mean ulcer size in the MMP12 GG-geno-
type compared with the other genotypes (PZ .001). Combining the present
results with our previous published data on the same population, we suggest
them to apply as tentative prognostic indicators in primary CVD.
Conclusion: By analyzing simultaneously selected SNPs, it might be possible
to glean precious information in predicting VLU onset or in stratifying
patients according to their potential to heal. Although significant, our find-
ings must be considered preliminary and the proposed prognostic indicators
considered with caution, before ulterior more extensive studies in different
populations can eventually confirm the present findings.
Clinical Relevance: The DNA-array evaluation could be added to clinical
CVD assessment. By analyzing simultaneously selected SNPs, it is possible
to have precious information in predicting VLU onset or in stratifying
patients according to their potential to heal. Prevention program in primary
CVD could be improved by using DNA-array evaluation in initial patient
assessment. Our results must be handled with extreme caution before
considering them as prognostic indicators in VLU, and further larger studies
in different populations are mandatory.Suggested objective performance goals and clinical trial design for
evaluating catheter-based treatment of critical limb ischemia
Michael S. Conte, Patrick J. Geraghty, Andrew W. Bradbury, Nathanael D.
Hevelone, Stuart R. Lipsitz, Gregory L. Moneta, Mark R. Nehler, Richard J.
Powell, Anton N. Sidawy
Objective: To develop a set of suggested objective performance goals (OPG)
for evaluating new catheter-based treatments in critical limb ischemia (CLI),
based on evidence from historical controls.
Methods: Randomized, controlled trials of surgical, endovascular, and phar-
macologic/biologic treatments for CLI were reviewed according to specified
criteria regarding study population and data quality. Line-item data were
obtained for selected studies from the sponsor/funding agency. A set of
specific outcome measures was defined in accordance with the treatment
goals for the CLI population. Risk factors were examined for their influence
on key endpoints, and models of stratification based on specific clinical and
anatomic variables developed. Sample size estimates were made for single-
arm trial designs based on comparison to the suggested OPG.
Results: Bypass with autogenous vein was considered the established stan-
dard, and data compiled from three individual randomized, controlled trials
(NZ 838) was analyzed. The primary efficacy endpoint was defined as peri-
operative (30-day) death or any major adverse limb event (amputation ormajor reintervention) occurring within one year. Results of open surgery
controls demonstrated freedom from the primary endpoint in 76.9% (95%
confidence interval [CI] 74.0%-79.9%) of patients at one year, with amputa-
tion-free survival (AFS) of 76.5% (95% CI 73.7%-79.5). An additional 3% non-
inferiority margin was suggested in generating OPG for catheter-based
therapies. Defined clinical (age > 80 years and tissue loss) and anatomic
(infra-popliteal anatomy or lack of good quality saphenous vein) risk
subgroups provided significantly different point estimates and OPG threshold
values.
Conclusions: For new catheter-based therapies in CLI, OPGs offer a feasible
approach for pre-market evaluation using non-randomized trial designs.
Such studies should incorporate risk stratification in design and reporting
as the CLI population is heterogeneous with respect to baseline variables
and expected outcomes. Guidelines for CLI trial design to address consis-
tency in study cohorts, methods of assessment, and endpoint definitions
are provided.
Aspirin resistance: Current evidence and clinical implications
George Kasotakis, Iraklis I. Pipinos, Thomas G. Lynch
Atherothrombosis, characterized by atherosclerotic plaque rupture and
subsequent occlusive or subocclusive thrombus formation is the primary
cause of acute ischemic syndromes involving all vascular beds and accounts
for more than one-third of all deaths in the developed world. Platelet acti-
vation and aggregation constitute the most critical component in the path-
ophysiology of atherothrombotic disease. Aspirin is currently the most
commonly used antiplatelet agent and one of the most frequently prescribed
drugs, with as many as 30 million Americans on chronic aspirin regimens.
Multiple well-designed prospective randomized clinical trials have demon-
strated aspirin’s efficacy in both primary and secondary prevention of a wide
variety of entities that the atherothrombotic disease spectrum encom-
passes, such as cerebrovascular, coronary artery, and peripheral vascular
disease. Despite its proven benefit, however, a growing body of evidence
suggests that up to 70% of aspirin-takers may still be at risk for atherothrom-
botic complications due to resistance. Patients with laboratory-confirmed
aspirin resistance seem to have an almost fourfold increase in their risk
for acute thrombotic episodes, which underlines the magnitude of the
problem for the vascular specialist. In this article, we review the physiology
of platelet activation and the role of aspirin as an antiplatelet agent; the
various laboratory assays used in assessing aspirin effectiveness; and current
data on aspirin resistance and its clinical implications in patients with
cardiovascular disease. We also review the studies that explore this phenom-
enon in patients with peripheral arterial disease and discuss the optimal
management options in aspirin-resistant individuals. Suggestions are
advanced for the direction of future trials evaluating aspirin resistance in
patients with vascular disease.
